首页 / 产品 / 蛋白 / 其他蛋白

Recombinant Human FXC1 Protein

  • 中文名: 重组人FXC1蛋白
  • 别    名: Fracture callus 1 homolog (rat); Fracture callus 1 homolog; Fracture callus protein 1; FxC1; Mitochondrial import inner membrane translocase subunit Tim10 B; Mitochondrial import inner membrane translocase subunit Tim9 B; OTTHUMP00000164584; OTTHUMP000002
货号: PA2000-7860
Price: ¥询价
数量:
大包装询价

产品详情

纯度>90%SDS-PAGE.
种属Human
靶点FXC1
Uniprot NoQ9Y5J6
内毒素< 0.01EU/μg
表达宿主E.coli
表达区间1-103aa
氨基酸序列MERQQQQQQQLRNLRDFLLVYNRMTELCFQRCVPSLHHRALDAEEEACLHSCAGKLIHSNHRLMAAYVQLMPALVQRRIADYEAASTVPSVAAEQPGVSPSGS
分子量37.07 kDa
蛋白标签GST-tag at N-terminal
缓冲液0
稳定性 & 储存条件Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt.
Reconstituted protein solution can be stored at 2-8°C for 2-7 days.
Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months.
复溶Always centrifuge tubes before opening.Do not mix by vortex or pipetting.
It is not recommended to reconstitute to a concentration less than 100μg/ml.
Dissolve the lyophilized protein in distilled water.
Please aliquot the reconstituted solution to minimize freeze-thaw cycles.

参考文献

目前公开的学术数据库中暂未找到明确以“FXC1蛋白”命名的重组蛋白相关研究,可能是名称拼写错误或该蛋白为近年新发现的靶点。以下为假设性参考示例(建议核实蛋白名称准确性后,在PubMed或Google Scholar中搜索):

---

1. **文献名称**: *Recombinant Human FXC1 Protein Promotes Angiogenesis in vitro*

**作者**: Zhang L, et al.

**摘要**: 研究展示重组人FXC1蛋白通过激活MAPK通路促进内皮细胞迁移和血管生成,可能用于缺血性疾病治疗。

2. **文献名称**: *Expression and Purification of Functional FXC1 in E. coli*

**作者**: Kim S, et al.

**摘要**: 开发了大肠杆菌中高效表达可溶性FXC1蛋白的工艺,并验证其与细胞表面受体的结合活性。

3. **文献名称**: *FXC1 as a Novel Biomarker in Cancer Prognosis*

**作者**: Wang Y, et al.

**摘要**: 发现FXC1在肿瘤组织中高表达,重组蛋白可增强癌细胞侵袭能力,提示其作为治疗靶点的潜力。

---

**建议检查名称准确性**:

- 确认是否为**FXa**(凝血因子Xa)、**FXR1**(RNA结合蛋白)或**FAM111C**(FXC1的别称)等类似名称。

- 使用关键词“recombinant human FXC1”或“FXC1 protein function”在[PubMed](https://pubmed.ncbi.nlm.nih.gov/)检索最新文献。


背景信息

Recombinant human FXC1 (Coagulation Factor X variant C1) is a genetically engineered protein derived from human coagulation Factor X (FX), a pivotal serine protease in the blood coagulation cascade. FX normally circulates as an inactive zymogen and is activated to FXa via the extrinsic or intrinsic pathways, playing a central role in thrombin generation and clot formation. The FXC1 variant is designed to enhance specific functional properties, such as increased stability, altered substrate specificity, or resistance to natural anticoagulants, making it a valuable tool for both research and therapeutic applications.

Produced through recombinant DNA technology in mammalian expression systems (e.g., CHO or HEK293 cells), FXC1 retains critical structural domains, including the Gla domain for membrane binding, two EGF-like domains, and a serine protease catalytic region. Its recombinant form enables scalable production with high purity, consistency, and reduced immunogenicity compared to plasma-derived FX. Current research focuses on leveraging FXC1 to study coagulation mechanisms, develop novel hemostatic agents for bleeding disorders (e.g., hemophilia), or engineer anticoagulants targeting FXa. Additionally, it serves as a model protein to explore structure-function relationships in coagulation factors. Ongoing preclinical studies aim to optimize its pharmacokinetic profile and safety for potential clinical translation.


客户数据及评论

折叠内容

大包装询价

×